Syneron Medical Ltd.  

(Public, NASDAQ:ELOS)   Watch this stock  
Find more results for ELOS
+0.06 (0.81%)
Dec 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.35 - 7.53
52 week 6.10 - 12.90
Open 7.46
Vol / Avg. 139,865.00/319,625.00
Mkt cap 276.88M
P/E     -
Div/yield     -
EPS -0.27
Shares 36.75M
Beta 1.28
Inst. own 70%
Feb 17, 2016
Q4 2015 Syneron Medical Ltd Earnings Release (Estimated) Add to calendar
Nov 17, 2015
Syneron Medical Ltd at Stifel Healthcare Conference
Nov 16, 2015
Syneron Medical Ltd at Barclays MedTech/Tools SMID Cap Day
Nov 16, 2015
Syneron Medical Ltd at Brean Capital Life Sciences Summit Conference
Nov 11, 2015
Q3 2015 Syneron Medical Ltd Earnings Release
Nov 11, 2015
Q3 2015 Syneron Medical Ltd Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -10.51% -2.03%
Operating margin -11.38% -0.87%
EBITD margin - 2.78%
Return on average assets -8.95% -1.70%
Return on average equity -11.92% -2.26%
Employees 659 -
CDP Score - -


Tavor Building 4 P.O. Box 550
YOKNEAM, 2069200
+972-7-32442200 (Phone)
+972-7-32442202 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Syneron Medical Ltd. is engaged in manufacture, research, development, marketing and sales of advanced equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company designs, develops and markets aesthetic medical products based on its various technologies, including Electro-Optical Synergy (ELOS) technology to provide aesthetic medical treatments. The Company's products targets an array of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, laser-assisted lipolysis and topical skin brightening products.

Officers and directors

Shimon Eckhouse Ph.D. Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Amit Meridor Chief Executive Officer
Bio & Compensation  - Reuters
Hugo Goldman Chief Financial Officer
Bio & Compensation  - Reuters
Erik Dowell Vice President-North America
Age: 43
Bio & Compensation  - Reuters
William Griffing Chief Executive Officer - Syneron Candela North America
Age: 48
Bio & Compensation  - Reuters
Shlomo Alkalay Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Robert Ruck Executive Vice President, Asia Pacific
Age: 54
Bio & Compensation  - Reuters
Robert Fielitz Vice President and Managing Director of Europe, Middle East and Africa
Age: 46
Bio & Compensation  - Reuters
Sarit Soccary Vice President-Strategy and Business Development
Age: 43
Bio & Compensation  - Reuters
Ilan Nacasch Chief Branding Officer
Age: 41
Bio & Compensation  - Reuters